RT @doctorRBC: First Head-to-Head bDMARD study in axSpA to assess radiographic progression - secukinumab vs. adalimumab
Tweet Content
First Head-to-Head bDMARD study in axSpA to assess radiographic progression
- secukinumab vs. adalimumab biosimilar
- 66% of either arm prevented radiographic progression
- no difference between two arms but good news is radiographic progression is low!
@RheumNow #RNL2023 https://t.co/xq8GhN7kzr
Show on Archive Page
On
Display in Search Results
On
PDQ
Off